



















The effect of oncolytic vaccinia  JX-594 in combination with transient 





平成 年 月 日現在３０   ６ ２０
円     3,000,000
研究成果の概要（和文）：腫瘍融解ウイルスJX-594と免疫抑制の併用によりウイルス増殖が促進し，治療抵抗性





研究成果の概要（英文）：Combination therapy of Oncolytic vaccinia virus JX-594 and immunosuppression
 has possibilities to overcome the treatment-resistant progressive cancer. Recently, it is known 
that cancer stem cells (CSCs) cause the treatment resistance. CSCs are suitable therapeutic targets 
for overcoming the treatment-resistance. We decided to research the efficacy of combination therapy 
of JX-594 and immunosuppression to hepatocellular carcinoma CSCs. However, to incubate CSCs stably 
was difficult, so that we have to establish the stable CSC's incubation method at first. We found 
that CD13 positive cells in hepatocellular carcinoma cell line, Li-7, had CSC features and those 
cells could be maintained stably by mTeSR1 medium. This result is useful to develop the new 
treatment for CSCs. We will apply this incubation method to research the efficacy of combination 






















第 2 相臨床試験が報告され(Heo J et al. 




















胞株 Li-7 において CD13+CD166-分画細胞
がCSCs様の特徴を持つことが報告されてい







で ， ま ず CSCs に お け る thymidine 
kinase(TK)の活性や JX-594の感染効率，殺
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